Prevention and treatment of hypertension or elevated blood pressure using phytase

Phytase administration addresses the ineffectiveness of current hypertension treatments by increasing essential nutrient bioavailability, effectively reducing blood pressure and managing hypertension symptoms, including when used with other medications.

WO2026236838A1PCT designated stage Publication Date: 2026-11-19ACCESS NUTRIENTS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050690
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for hypertension and elevated blood pressure are often ineffective, particularly in cases of resistant or refractory hypertension, and there is a need for alternative methods that can effectively manage and reduce blood pressure levels.

Method used

Administering an appropriate amount of phytase, a phosphatase enzyme, to increase the bioavailability of iron, zinc, and phosphate, thereby addressing deficiencies associated with hypertension and elevated blood pressure, which can be sourced from various fungi or genetically modified variants, and formulated for oral or intravenous administration.

Benefits of technology

Phytase administration leads to measurable reductions in systolic and diastolic blood pressure, maintaining blood pressure within target ranges and alleviating symptoms, even when used alongside conventional anti-hypertensive medications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050690_19112026_PF_FP_ABST
    Figure CA2026050690_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides methods for preventing or treating hypertension, or preventing or treating elevated blood pressure in a subject. The methods comprise administering phytase to the subject.
Need to check novelty before this filing date? Find Prior Art

Description

PREVENTION AND TREATMENT OF HYPERTENSION OR ELEVATED BLOOD PRESSURE USING PHYTASEFIELD

[0001] The present disclosure relates generally to methods of preventing or treating hypertension and elevated blood pressure using phytase.BACKGROUND

[0002] The following paragraphs are not an admission that anything discussed in them is prior art or part of the knowledge of persons skilled in the art.

[0003] Hypertension is a disorder, disease, or condition characterized by an elevated blood pressure in a subject at rest. Generally, a subject may be characterized as having a healthy blood pressure if their systolic blood pressure is < 120 mmHg and their diastolic blood pressure is < 80 mmHg (i.e., < 120 / < 80 mmHg) according to the 2017 American College of Cardiology / American Heart Association (ACC / AHA) guidelines (Whelton, P. K. et al. (2018)). According to the 2017 ACC / AHA guidelines, a subject’s blood pressure may be characterized as “elevated” if their blood pressure is 120-129 / < 80 mmHg. According to the 2017 ACC / AHA guidelines, a subject may be diagnosed as hypertensive if their systolic blood pressure is measured at > 130 mm Hg, and / or their diastolic blood pressure is measured at > 80 mm Hg. According to the 2017 ACC / AHA guidelines, a subject may be “stage 1 hypertensive” if their systolic blood pressure is measured between 130-139 mmHg, and / or their diastolic blood pressure is measured between 80-89 mmHg. According to the 2017 ACC / AHA guidelines, a subject may be “stage 2 hypertensive” if their systolic blood pressure is measured at > 140 mmHg, and / or their diastolic blood pressure is measured at > 90 mmHg. According to the 2017 ACC / AHA guidelines, a subject may be diagnosed with “malignant hypertension” or a “hypertensive crisis” if their systolic blood pressure is measured at > 180 mmHg, and / or their diastolic blood pressure is measured at > 120 mmHg. Hypertension may be classified as “primary hypertension” if it gradually develops over several years due to an unknown cause, or “secondary hypertension” if it develops as a symptom of a known underlying disorder, disease, or condition. Hypertension may be classified as “resistant hypertension” if it persists in a subject over a period of several months (e.g., six months) despite the subject being treated with 3 or 4 different anti-hypertensive medications at their maximally or near-maximally tolerated dosages (including a diuretic), or“refractory hypertension” if the hypertension is similarly resistant to treatment with 5 or more different anti-hypertensive medications at their maximal or near-maximal dosages (including a long-acting thiazide-like diuretic, and a mineralocorticoid receptor antagonist). “Chronic hypertension” is characterized as Stage 1 hypertension or higher in a subject that persists for a prolonged period (e.g., over several months). Hypertension is commonly characterized by several symptoms including severe headache, chest pain, dizziness, vertigo, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack or heart failure.

[0004] Phytate or phytic acid is the principal storage form of phosphorus in many plant tissues, especially bran and seeds. Phytic acid is also referred to as inositol hexaphosphate (I P6) or inositol polyphosphate. Phytase is a phosphatase enzyme that catalyzes the hydrolysis of phytic acid.INTRODUCTION

[0005] The following introduction is intended to introduce the reader to this specification but not to define any invention. One or more inventions may reside in a combination or sub-combination of the instrument elements or method steps described below or in other parts of this document. The inventor does not waive or disclaim their rights to any invention or inventions disclosed in this specification merely by not describing such other invention or inventions in the claims.

[0006] The present disclosure provides methods for preventing or treating hypertension using phytase. The present disclosure also provides methods for preventing or treating elevated blood pressure using phytase. The inventor has discovered that administering an appropriate or effective amount of phytase can decrease or maintain blood pressure in subjects with hypertension or elevated blood pressure and / or maintain blood pressure at acceptable levels in subjects who are recovering from, or prone to, hypertension or elevated blood pressure. Without being bound by theory, the inventors believe that an appropriate or effective amount of phytase administered to a subject can: 1) increase the bioavailability of iron whose deficiency has been associated with hypertension or elevated blood pressure; 2) increase the bioavailability of zinc whose deficiency has been associated with hypertension or elevated blood pressure; and / or 3) increase the bioavailability of phosphate whose deficiency has been associated with hypertension or elevated blood pressure. Further, the inventor has found that an amount less than or greater than anappropriate or effective amount of phytase administered to a subject may not sufficiently prevent or treat hypertension or elevated blood pressure.

[0007] The present disclosure provides methods for reducing, maintaining, preventing, and / or treating elevated blood pressure and / or hypertension in a subject by administering phytase. In some embodiments, administration of an effective amount of phytase produces a measurable reduction in systolic and / or diastolic blood pressure relative to a baseline value, and / or maintains blood pressure within a target range. In some embodiments, administration is performed according to a pre-specified dosing protocol (e.g., fixed dose units and fixed daily totals).

[0008] The present disclosure also discusses compositions comprising phytase, and uses of phytase for preventing or treating hypertension, and for preventing or treating elevated blood pressure.

[0009] The present disclosure provides a method for preventing or treating hypertension in a subject, comprising administering phytase to the subject. The subject may be administered from about 400 FTU to about 1,000,000 FTU or from about 400 FTU to about 5000 FTU of phytase per day. The subject may be measured at least once as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, at least once prior to being administered an initial dose of the phytase, or on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

[0010] The present disclosure also provides a method for preventing or treating elevated blood pressure in a subject, comprising administering phytase to the subject. The subject may be administered from about 400 FTU to about 1,000,000 FTU or from about 400 FTU to about 5000 FTU of phytase per day. The subject may be measured at least once as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, at least once prior to being administered an initial dose of the phytase, or on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

[0011] The present disclosure provides that the method may comprise phytase being administered in a dose of from about 190 FTU to about 2000 FTU, for example, about 800 FTU. It also provides that the method may comprise phytase being administered once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day, 10 times per day, 11 timesper day, 12 times per day, 13 times per day, 14 times per day, 15 times per day, 16 times per day, 17 times per day, 18 times per day, 19 times per day, 20 times per day, 21 times per day, 22 times per day, 23 times per day, 24 times per day, 25 times per day, 26 times per day, or more. It further provides that the method may comprise phytase being administered to the subject for a duration of from about 1 day to about 360 days, for example, about 28 days, or for the lifetime of the subject.

[0012] The present disclosure provides that the method may comprise the subject suffering from one or more of the following symptoms: severe headache, chest pain, dizziness, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack, or heart failure.

[0013] The present disclosure provides that the method may comprise phytase being co-administered with one or more of the following anti-hypertensive medication(s): an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a calcium channel blocker, a diuretic, Sandoz Valsartan HCT, a statin, an anti-platelet medication, an anti-coagulant, a nitrate, an aldosterone antagonist, Digoxin, an anti-arrhythmic medication, a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor, or an angiotensin receptor-neprilysin inhibitor (ARNI). The phytase may be co-administered concurrently or non-concurrently with the one or more anti-hypertensive medication(s). The present disclosure provides that the method may comprise a phytase being a wild-type phytase sourced from Aspergillus ficuum or Aspergillus niger, or a wild-type phytase sourced from a species of fungi of the genera Myceliophthora, Mucor, Penicillium, Rhizopus, or Trichoderma.

[0014] The present disclosure provides for use of phytase and phytase for use in preventing or treating hypertension in a subject, or for preparing a medicament for preventing or treating hypertension in a subject, wherein about 400 FTU to about 1,000,000 FTU or from about 400 FTU to about 5000 FTU of phytase may be for administration to the subject per day. The present disclosure further provides for use of a composition comprising phytase and a composition comprising phytase for use in preventing or treating hypertension in a subject, wherein the composition is for administration to the subject. The composition may comprise from about 400 FTU to about 1,000,000 FTU or from about 190 FTU to about 2000 FTU of phytase. The composition may further comprise a pharmaceutically acceptable carrier or excipient, zinc, micronutrient, vitamin, and / or mineral. The present disclosureprovides for use of the phytase, the medicament, or the composition comprising phytase for preventing or treating hypertension in a subject who has been measured at least once as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, at least once prior to the administration of an initial dose of the phytase, or on at least three or more days during a three-month period preceding the administration of an initial dose of the phytase.

[0015] The present disclosure provides for use of phytase and phytase for use in preventing or treating elevated blood pressure in a subject, or for preparing a medicament for preventing or treating elevated blood pressure in a subject, wherein about 400 FTU to about 1,000,000 FTU or from about 400 FTU to about 5000 FTU of phytase may be for administration to the subject per day. The present disclosure further provides for use of a composition comprising phytase and a composition comprising phytase for use in preventing or treating elevated blood pressure in a subject, wherein the composition is for administration to the subject. The composition may comprise from about 400 FTU to about 1,000,000 FTU or from about 190 FTU to about 2000 FTU of phytase. The composition may further comprise a pharmaceutically acceptable carrier or excipient, zinc, micronutrient, vitamin, and / or mineral. The present disclosure provides for use of the phytase, the medicament, or the composition comprising phytase for preventing or treating elevated blood pressure in a subject who has been measured at least once as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, at least once prior to being administered an initial dose of the phytase, or on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

[0016] The present disclosure provides for use of phytase and phytase for use in preventing or treating hypertension or elevated blood pressure in a subject, or for preparing a medicament for preventing or treating hypertension or elevated blood pressure in a subject, or for use of a composition comprising phytase to prevent or treat hypertension or elevated blood pressure in a subject wherein the phytase or the composition is for administration in a dose of from about 190 FTU to about 2000 FTU, for example, about 800 FTU. The present disclosure provides for use of the phytase, the medicament, or the composition comprising phytase wherein the phytase or composition comprising phytase is for administration once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day, 10 times per day, 11times per day, 12 times per day, 13 times per day, 14 times per day, 15 times per day, 16 times per day, 17 times per day, 18 times per day, 19 times per day, 20 times per day, 21 times per day, 22 times per day, 23 times per day, 24 times per day, 25 times per day, 26 times per day, or more. The present disclosure further provides for use of the phytase, the medicament, or the composition comprising phytase wherein the phytase or the composition comprising phytase are administered to the subject for a duration of from about 1 day to about 360 days, for example, about 28 days, or for the lifetime of the subject.

[0017] The present disclosure provides for use of the phytase, the medicament or the composition comprising phytase for preventing or treating hypertension or elevated blood pressure in a subject suffering from one or more of the following symptoms: severe headache, chest pain, dizziness, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack, or heart failure. The phytase or composition comprising phytase may be co-administered with one or more of the following anti-hypertensive medication(s): an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a calcium channel blocker, a diuretic, Sandoz Valsartan HCT, a statin, an anti-platelet medication, an anti-coagulant, a nitrate, an aldosterone antagonist, Digoxin, an anti-arrhythmic medication, a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor, or an angiotensin receptor-neprilysin inhibitor (ARNI). The phytase or composition comprising phytase may be co-administered concurrently or non-concurrently with the one or more antihypertensive medication(s). The present disclosure provides for use of phytase for preventing or treating elevated blood pressure in a subject, or for preparing a medicament for preventing or treating elevated blood pressure in a subject, or use of a composition comprising phytase for treating or preventing elevated blood pressure in a subject wherein the phytase is a wild-type phytase sourced from Aspergillus ficuum or Aspergillus niger, or a wild-type phytase sourced from species of fungi of the genera Myceliophthora, Mucor, Penicillium, Rhizopus, or Trichoderma.

[0018] Other aspects and features of the present disclosure will become apparent to those ordinarily skilled in the art upon review of the following description of specific examples in conjunction with the accompanying figures.BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Examples of the presently disclosed methods and uses will now be described, by way of example only, with reference to the attached Figures.

[0020] Fig. 1 is graphs showing the effect of the herein disclosed phytase administration on systolic and diastolic blood pressure in a subject.

[0021] Fig. 2 is graphs showing the effect of the herein disclosed phytase administration on blood pressure in a subject, and the effect of ceasing administration of the phytase on blood pressure in the subject.

[0022] Fig. 3 is graphs showing the effect of the herein disclosed phytase administration on blood pressure in a subject being co-treated with propranolol.

[0023] Fig. 4 is graphs showing the effect of the herein disclosed phytase administration on systolic and diastolic blood pressure in two groups of subjects.DETAILED DESCRIPTION

[0024] Generally, the present disclosure provides a method for preventing or treating hypertension in a subject, comprising: administering phytase to the subject. The present disclosure also provides a method for preventing or treating elevated blood pressure in a subject, comprising: administering phytase to the subject.

[0025] In the context of the present disclosure, blood pressure is characterized as X / Y mmHg, wherein X represents a subject’s systolic blood pressure, wherein Y represents the subject’s diastolic blood pressure, and wherein both X and Y are measured in the subject at rest. Blood pressure may be based on an average of > two X and Y measurements obtained on > two occasions. Blood pressure may be recorded using a blood pressure device at home, in a commercial store or pharmacy, or by a medical professional in a clinical or hospital setting. Unless otherwise stated, a reading of “X I Y mmHg” will be understood to mean that the subject is recorded as having a blood pressure of X mmHg and Y mmHg, i.e., not X mmHg or Y mmHg, or X mmHg and / or Y mmHg.

[0026] In the context of the present disclosure, hypertension refers to a systolic blood pressure of > 130 mmHg and / or a diastolic blood pressure of > 80 mmHg. The herein disclosed hypertension includes stage 1 hypertension, stage 2 hypertension, malignant hypertension, and hypertensive crisis, as defined in the 2017 ACC / AHA guidelines. In the context of the present disclosure, elevated blood pressure refers to a systolic blood pressure of 121-129 mmHg and a diastolic blood pressure of < 80 mmHg. Unless otherwise stated,reference to healthy blood pressure, elevated blood pressure, and hypertension relate to the systolic and diastolic blood pressures defined in the 2017 ACC / AHA guidelines. As used herein, “prehypertension” may refer to subjects meeting criteria for elevated blood pressure as defined above, and / or other clinically used prehypertension criteria, unless the context indicates otherwise.

[0027] Preventing or treating hypertension refers to an action that can: 1) reduce the likelihood of developing hypertension, delay hypertension onset, or keep hypertension from occurring; 2) reverse or relieve existing hypertension; 3) inhibit the progress and / or further development of hypertension; 4) palliate one or more symptoms of hypertension; and / or 5) prevent the recurrence of hypertension. Preventing or treating elevated blood pressure refers to an action that can: 1) reduce the likelihood of developing elevated blood pressure, delay elevated blood pressure onset, or keep elevated blood pressure from occurring; 2) reverse or relieve existing elevated blood pressure; 3) inhibit the progress and / or further development of elevated blood pressure; 4) palliate one or more symptoms of elevated blood pressure; and / or 5) prevent the recurrence of elevated blood pressure.

[0028] In the context of the present disclosure, phytase refers to any phosphatase enzyme that catalyzes the hydrolysis of phytic acid. Phytase may be sourced as wild-type phytase expressed from Aspergillus niger, Aspergillus ficuum, or as wild-type phytase expressed from a species of fungi of the genera Myceliophthora, Mucor, Penicillium, Rhizopus, or Trichoderma, or the new protein tyrosine phosphatase-like phytase expressed from the gut bacteria of ruminant animals, or any genetically modified phytase variant derived therefrom. Sourcing phytase from wild-type Aspergillus ficuum may be advantageous because it has a broad pH range, which is helpful for digestion in the human gastrointestinal (Gl) system. Sourcing phytase from genetically modified Aspergillus ficuum or Aspergillus niger may be further advantageous because the phytase may be more efficient at metabolizing phytate. The phytase may be formulated for oral administration, for example, as a dry or liquid form within a capsule, or for intravenous administration, for example, as a sterile injectable solution.

[0029] “Appropriate or effective amount” means an amount of phytase that, when administered to a subject as described herein, is sufficient to produce a measurable therapeutic effect on blood pressure, including (i) a reduction in systolic and / or diastolic blood pressure relative to a baseline value, (ii) maintenance of systolic and / or diastolic bloodpressure within a target range, and / or (iii) prevention of an increase in systolic and / or diastolic blood pressure, as measured using the blood pressure measurement procedures described herein. As used herein, “baseline blood pressure” or “based value” refers to a blood pressure value determined prior to initiation of phytase administration, optionally as an average of multiple measurements obtained over multiple occasions during a preadministration period.

[0030] The amount of the herein disclosed phytase administered to a subject may be any appropriate or effective amount to sufficiently prevent or treat hypertension, or to sufficiently prevent or treat elevated blood pressure, in a subject over an administration period ranging from about 24 hours to about 360 days, or for the lifetime of the subject, for example, from about 400 FTU to about 1,000,000 FTU or from about 400 FTU to about 5000 FTU; about 400 FTU; about 500 FTU; about 600 FTU; about 700 FTU; about 800 FTU; about 900 FTU; about 1000 FTU; about 1500 FTU; about 2000 FTU; about 2500 FTU; about 3000 FTU; about 3500 FTU; about 4000 FTU; about 4500 FTU; about 5000 FTU; about 5500 FTU; about 6000 FTU; about 6500 FTU; about 7000 FTU; about 7500 FTU; about 8000 FTU; about 8500 FTU; about 9000 FTU; about 10,000 FTU; about 25,000 FTU; about 50,000 FTU; about 75,000 FTU; about 100,000 FTU; about 200,000 FTU; about 300,000 FTU; about 400,000 FTU; about 500,000 FTU; about 600,000 FTU; about 700,000 FTU; about 800,000 FTU; about 900,000 FTU; about 1,000,000 FTU; per day; or from any one of the recited FTUs to any other of the recited FTUs. One phytase unit (FTU) is the activity of phytase required to liberate 1 pmol of inorganic phosphorus per minute at pH 5.5 from an excess of 15 M sodium phytate at 37°C.

[0031] An appropriate or effective amount of the herein disclosed phytase administered to a subject may be an amount that causes a subject’s systolic and / or diastolic blood pressure to decrease, for example, from a hypertension blood pressure or elevated blood pressure level to a healthy blood pressure. In some examples according to the present disclosure, an appropriate or effective amount of phytase administered to a subject may cause a subject’s systolic blood pressure to decrease, for example, by from about 1% to about 30%; about 1%; about 2%; about 3%; about 4%; about 5%; about 10%; about 15%; about 20%; about 25%; about 30%; or from any one of the recited percentages to any other of the recited percentages, over an administration period ranging from about 24 hours to about 360 days, or for the lifetime of the subject. In some examples according to the present disclosure, an appropriate or effective amount of phytase administered to a subject maycause a subject’s diastolic blood pressure to decrease, for example, by from about 1% to about 30%; about 1%; about 2%; about 3%; about 4%; about 5%; about 10%; about 15%; about 20%; about 25%; about 30%; or from any one of the recited percentages to any other of the recited percentages, over an administration period ranging from about 24 hours to about 360 days, or for the lifetime of the subject.

[0032] An appropriate or effective amount of the herein disclosed phytase administered to a subject may be an amount that maintains a subject’s systolic blood pressure within 8% of a healthy systolic blood pressure, for example, from about 120 mmHg to about 129 mmHg; about 120 mmHg; about 121 mmHg; about 122 mmHg; about 123 mmHg; about 124 mmHg; about 125 mmHg; about 126 mmHg; about 127 mmHg; about 128 mmHg; or about 129 mmHg. An appropriate or effective amount of the herein disclosed phytase administered to a subject may be an amount that maintains a subject’s diastolic blood pressure below about 80 mmHg.

[0033] The herein disclosed amount of phytase may be administered in one or more doses, each dose comprising from about 190 FTU to about 2000 FTU, for example, about 190 FTU; about 200 FTU; about 300 FTU; about 400 FTU; about 500 FTU; about 600 FTU; about 700 FTU; about 800 FTU; about 900 FTU; about 1000 FTU; about 1500 FTU; about 2000 FTU; or from any one of the recited FTUs to any other of the recited FTUs. The amount of phytase formulated in a dose may be about 800 FTU, for example, when decreasing the number of phytase administrations is desired.

[0034] The herein disclosed amount of phytase may be administered to a subject from about once per day to about 26 times per day or more, for example, once per day; twice per day; three times per day; four times per day; five times per day; six times per day; seven times per day; eight times per day; nine times per day; 10 times per day; 11 times per day; 12 times per day; 13 times per day; 14 times per day; 15 times per day; 16 times per day; 17 times per day; 18 times per day; 19 times per day; 20 times per day; 21 times per day; 22 times per day; 23 times per day; 24 times per day; 25 times per day; 26 times per day; or more. In some examples according to the present disclosure, phytase is administered twice per day, for example, one dose in the morning of the day and a second dose in the afternoon of the day, when convenience of administration is desired. The herein disclosed amount of phytase may be administered to a subject intermittently, for example, every other day; every 3 days; every 4 days; every 5 days; every 6 days; every 7 days; every other week; 1 day per week; 2 days per week; 3 days per week; 4 days per week; 5 days per week; or 6 days perweek, or in cycles such as 1 day on and 6 days off; 2 days on and 5 days off; 3 days on and 4 days off; 4 days on and 3 days off; 5 days on and 2 days off; or 6 days on and 1 day off.

[0035] The herein disclosed phytase may be administered to a subject for a sufficient length of time to prevent or treat hypertension, or to prevent or treat elevated blood pressure, for example, for a duration of from about 1 day to about 360 days or for the lifetime of the subject, for example, about 1 day; about 5 days; about 7 days; about 10 days; about 14 days; about 21 days; about 28 days; about 30 days; about 60 days; about 90 days; about 120 days; about 180 days; about 210 days; about 240 days; about 270 days; about 300 days; about 360 days; about 365 days; or from any one of the recited days to any other of the recited days.

[0036] The daily dose, dosing intervals, and duration may be pre-specified according to a protocol (e.g., fixed dose units and fixed daily totals), thereby reducing or avoiding the need for individualized dose titration.

[0037] The herein disclosed phytase may be administered to a subject in proximity to the beginning of a meal, for example, from about 60 minutes prior to beginning a meal to about 180 minutes after beginning a meal. Proximity to a meal refers to a period near in time to the beginning of a meal. In the context of the present disclosure, meal refers to traditional meals and meal times; however, these also include the ingestion of any substance regardless of size and / or timing. Alternatively, phytase may be administered in remoteness to the beginning of a meal, for example, greater than 60 minutes prior to beginning a meal and greater than 180 minutes after beginning a meal.

[0038] The herein disclosed phytase may be administered in solid form, for example powder form, or in liquid form. The solid or liquid form may be formulated within a suitable capsule. Phytase may be administered orally or intravenously. Phytase may be administered as part of a composition. The composition may further comprise a pharmaceutically acceptable carrier or excipient, zinc, micronutrients, vitamins, and / or minerals.

[0039] The herein disclosed amount, dose, and / or duration of the administration of phytase to a subject may be adjusted to cause the amount of medicine and / or treatment administered to the subject alone, e.g., without phytase, to prevent or treat hypertension, or to prevent or treat elevated blood pressure, to be reduced by from about 5% to about 95%, for example, about 5%; about 10%; about 15%; about 20%; about 25%; about 30%; about 35%; about 40%; about 45%; about 50%; about 55%; about 60%; about 65%; about 70%; about 75%; about 80%; about 85%; about 90%; about 95%; 100%; or from any one of therecited percentages to any other of the recited percentages. The reduction may be observed following from about 1 day to about 180 days of the herein disclosed administration, for example, about 1 day; about 2 days; about 3 days; about 4 days; about 5 days; about 6 days; about 7 days; about 8 days; about 9 days; about 10 days; about 11 days; about 12 days; about 13 days; about 14 days; about 21 days; about 28 days; about 30 days; about 35 days; about 40 days; about 45 days; about 50 days; about 60 days; about 120 days; about 180 days; or from any one of the recited days to any other of the recited days.

[0040] The medicine and / or treatment to prevent or treat hypertension, or to prevent or treat elevated blood pressure, may be angiotensin-converting enzyme (ACE) inhibitors (e.g., Lisinopril (Zestril®), Enalapril (Vasotec®), Ramipril (Altace®), Captopril (Capoten®)), angiotensin II receptor blockers (ARBs) (e.g., Losartan (Cozaar®), Valsartan (Diovan®), Olmesartan (Benicar®)), beta-blockers (e.g., Atenolol (Tenormin®), Metoprolol (Lopressor®), Carvedilol (Coreg®)), calcium channel blockers (e.g., Amlodipine (Norvasc®), Diltiazem (Cardizem®), Verapamil (Calan®, Verelan®), diuretics (e.g., Hydrochlorothiazide (Hydrodiuril®), Furosemide (Lasix®), Spironolactone (Al dado ne®)), Sandoz Valsartan HCT (Co-Diovan®), statins (e.g., Atorvastatin (Lipitor®), Simvastatin (Zocor®), Rosuvastatin (Crestor®), Pravastatin (Pravachol®)), anti-platelet medications (e.g., Acetylsalicylic acid (Aspirin®), Clopidogrel (Plavix®), Ticagrelor (Brilinta®)), anti-coagulants (e.g., Warfarin (Jantoven®), Apixaban (Eliquis®), Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®)), nitrates (e.g., Nitroglycerin, Isosorbide dinitrate), aldosterone antagonists (e.g., Spironolactone (Aldactone®)), Digoxin (Lanoxin®), anti-arrhythmic medications (e.g., Amiodarone (Cordarone®), Flecainide (Tambocor®), Sotalol (Betapace®)), proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors (e.g., Alirocumab (Praluent®), Evolocumab (Repatha®)), angiotensin receptor-neprilysin inhibitors (ARNIs) (e.g., Sacubitril / valsartan (Entresto®)), or any combination thereof.

[0041] Phytase may be administered to a subject with a sufficient amount of one or more anti-hypertensive medications for treating or alleviating one or more symptoms associated with hypertension, such as severe headache, chest pain, dizziness, vertigo, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack or heart failure.

[0042] Phytase may be administered to a subject with a sufficient amount of one or more anti-hypertensive medications for treating or preventing hypertension, or for treating orpreventing elevated blood pressure, for example, ACE inhibitors, ARBs, beta blockers, calcium-channel blockers, diuretics, Sandoz Valsartan HCTZ, statins, anti-platelet medications, anti-coagulants, nitrates, aldosterone antagonists, Digoxin, anti-arrhythmic medications, PCSK9 inhibitors, ARNIs, or any combination thereof as prescribed by a physician. The phytase may be administered in combination with the one or more antihypertensive medication(s), concurrently with the one or more anti-hypertensive medication(s), or non-concurrently with the one or more anti-hypertensive medication(s). Concurrently refers to administration at the same time but not necessarily at the same part of the body. In some examples according to the present disclosure, one or more antihypertensive medication(s) is / are administered in the morning and evening, from about 8 hours prior to the administration of phytase to about 8 hours after the administration of phytase. Alternatively, the one or more anti-hypertensive medication(s) is / are administered less than 8 hours prior to the administration of phytase to about less than 8 hours after the administration of phytase. The one or more anti-hypertensive medication(s) may be combined with phytase in a composition for administration.

[0043] The present inventors observed in some embodiments that administering phytase to a subject may prevent or treat hypertension or elevated blood pressure.EXAMPLES

[0044] Example 1 - Case Study with Chronic Hypertension

[0045] SL is a male who was diagnosed with hypertension. SL has received no previous medication to treat his hypertension. Prior to starting treatment (Day 0), SL had a blood pressure of 133 / 83 mmHg. SL started taking 3 capsules of phytase per day for 34 days. SL then started taking 2 capsules of phytase per day for an additional 50 days. Table 1 illustrates a record of SL’s daily measurements of systolic and diastolic blood pressure. SL recorded his blood pressure measurements using a personal blood pressure device at home while at rest. On average, SL showed a 7.14% reduction in his systolic blood pressure and a 7.08% reduction in his diastolic blood pressure while taking 3 capsules of phytase per day between D9 and D33 relative to DO. SL subsequently showed an average reduction of 8.65% in his systolic blood pressure and 8.58% in his diastolic blood pressure while taking 2 capsules of phytase per day between D54 to D84 relative to DO. SL experienced no adverse symptoms before or while taking phytase.

[0046] Table 1. Daily measurements systolic and diastolic blood pressure (BP) for SL Day Systolic BP (mmHg) Diastolic BP (mmHg) Number of Phytase Capsules per Day 0 133 83 39 126 81 312 124 74 314 118 71 320 123 81 322 131 82 325 115 74 327 131 79 333 120 75 3Average change in BP -7.14% -7.08%between D9 and D33relative to Day 054 131 83 259 131 81 267 109 62 271 121 70 273 120 76 279 121 83 282 117 72 284 122 80 2Average change in BP -8.65% -8.58%between D54 to D84relative to Day 0

[0047] Example 2 - Case Study with Chronic Hypertension

[0048] LL is a female who was diagnosed with hypertension. Before taking phytase, LL had experienced a few symptoms associated with hypertension during the preceding 20 years, including vertigo, lightheadedness, and nausea. LL was receiving Sandoz® Valsartan HCTZ (160 mg I 12.5 mg) by oral administration once per day each morning, and Sandoz® Valsartan (80 mg) by oral administration once per day each evening, but her condition was still poorly managed. Prior to starting treatment (Day 0), LL had a blood pressure of 136 / 84 mmHg. LL started taking 2 capsules of phytase per day at 3pm for 9 days. LL then started taking 1 capsule of phytase per day for 3 days before stopping administration of phytase forthe subsequent 72 days. While taking phytase, LL had reportedly experienced fewer episodes of vertigo, lightheadedness, and nausea. However, LL had reduced her daily dosage of phytase from 2 capsules to 1 capsule after experiencing some lightheadedness due to low blood pressure. Table 2 illustrates a record of LL’s daily measurements of resting systolic and diastolic blood pressure. LL recorded her blood pressure measurements using a personal blood pressure device at home while at rest. On average, LL showed a 14.9% reduction in her systolic blood pressure, and a 13.3% reduction in her diastolic blood pressure, after at least 12 days of treatment with 1-2 capsules of phytase per day. Of note, this observable effect was lost within a few days of LL stopping administration of phytase as her systolic and diastolic blood pressure returned to about pre-treatment levels (i.e. , at DO) between D15 to D84.

[0049] Table 2. Daily measurements systolic and diastolic blood pressure (BP) for LL Day Systolic BP (mmHg) Diastolic BP (mmHg) # of Capsules per Day 0 136 84 21 127 84 22 130 79 23 122 80 24 125 76 25 111 75 26 100 63 27 112 71 28 116 73 29 100 59 110 120 76 111 110 65 1Average change in BP -14.9% -13.3%between D1 to D11relative to DO15 147 85 020 141 86 076 137 80 077 142 80 078 134 82 079 139 84 080 136 79 081 141 82 083 154 84 084 140 86 0Average change in BP +28.3% +27.4%between D15 to D84relative to D11Average change in BP +3.8% -1.4%between D15 to D84relative to DO

[0050] Example 3 - Case Study with Chronic Hypertension

[0051] KS is a male who was diagnosed with hypertension. KS has historically been taking propranolol (30 mg, twice a day) to treat his hypertension, but it had been insufficient to reduce his blood pressure. Immediately prior to starting treatment (Day 0), KS had a blood pressure of 139 / 67 mmHg. KS started taking several capsules of phytase per day during a 58-day period while taking propranolol. From DO to D15, KS took 2-6 capsules of phytase per day while taking 30 mg of propranolol twice per day (60 mg propranolol / day), with the exception of D14 when no capsules of phytase were taken. From D16 to D29, KS was unable to take any capsules of phytase due to a lack of supply, but continued treatment with 30 mg of propranolol twice per day. From D30 to D36, KS resumed taking 2 capsules of phytase twice per day (4 capsules of phytase / day) while continuing co-treatment with 30 mg propranolol twice per day. From D37 to D40, KS took 2 capsules of phytase per day while reducing his dosage of propranolol to 20 mg twice per day (40 mg propranolol / day). From D41 to D49, KS took 2-6 capsules of phytase per day while reducing his dosage of propranolol further to 10 mg twice per day (20 mg propranolol / day). From D50 to D56, KS took 4-5 capsules of phytase per day while increasing his daily dosage of propranolol to 50 mg (two daily doses, 20 mg then 30 mg). On D57, KS took 3 capsules of phytase as well as 20 mg of propranolol. Table 3 illustrates a record of KS’s daily blood pressure measurements, wherein “N / A” will be understood to indicate a date upon which no daily blood pressure measurement was recorded, “(P x #)” will be understood to indicate the number # of phytase capsules taken by KS at a given time of day, and (Pro10, Pro20, or Pro30) will be understood to indicate the time of day at which KS took a 10 mg, 20 mg, or 30 mg dose of propranolol, respectively. KS recorded his blood pressure measurements at least once per day between DO to D36 and D57, and between 2-7 times per day between D37 toD56 (wherein the time and blood pressure for each measurement is provided along with an average for all blood pressure readings for that day). Overall, KS showed an average reduction of 10.2% in his daily systolic blood pressure and an average increase of 22.6% in his daily diastolic blood pressure relative to DO. Between D1 to D36, KS showed an average reduction of 9.35% in his daily systolic blood pressure and an average increase of 24.7% in his diastolic blood pressure relative to DO while being co-treated with phytase and propranolol (60 mg / day). Notably, these effects appeared to slightly improve between D37 to D49 when KS reduced his daily dosage of propranolol (i.e., to 20 - 40 mg propranolol / day). During the latter period, KS showed an average reduction of 11.6% - 12.6% in his daily systolic blood pressure and only an average increase of 18.2% - 18.6 % in his daily diastolic blood pressure. It may be noted that KS showed an average diastolic blood pressure of 82.6 mmHg between D-5 to D-1 prior to starting treatment (not shown). Thus, it is possible that phytase treatment had little or no effect on KS’s diastolic blood pressure, and that the observed effect is attributable to an abnormally low reading at DO.

[0052] Table 3. Daily measurements of systolic and diastolic blood pressure (BP) for KSDay Systolic BP (mmHg) Diastolic BP (mmHg) Number of Propranolol Phytase per Day Capsules perDay0 139 67 2 30 mg x 2 1 132 90 2 30 mg x 2 2 137 88 4 30 mg x 2 3 132 90 4 30 mg x 2 4 130 83 4 30 mg x 2 5 123 88 4 30 mg x 2 6 127 81 6 30 mg x 2 7 123 78 6 30 mg x 2 8 135 93 6 30 mg x 2 9 130 80 6 30 mg x 2 10 123 78 4 30 mg x 2 11 128 86 4 30 mg x 2 12 N / A N / A 4 30 mg x 2 13 N / A N / A 2 30 mg x 2 14 N / A N / A N / A N / A136 98 2 30 mg x 2 125 86 0 30 mg x 2 105 72 0 30 mg x 2 130 80 0 30 mg x 2 115 78 0 30 mg x 2 126 84 0 30 mg x 2 128 85 0 30 mg x 2 131 86 0 30 mg x 2 N / A N / A N / A N / A 124 79 0 30 mg x 2 N / A N / A 0 30 mg x 2 131 76 0 30 mg x 2 125 87 0 30 mg x 2 122 81 0 30 mg x 2 116 80 0 30 mg x 2 121 93 4 30 mg x 2 121 83 4 30 mg x 2 110 71 4 30 mg x 2 128 81 4 30 mg x 2 131 84 4 30 mg x 2 N / A N / A 4 30 mg x 2 135 88 4 30 mg x 2 10:54 - 124 (P x 2) (Pro20) 10:54 - 81 (P x 2) (Pro20) 4 20 mg x 2 16:45 - 121 16:45 - 8122:00 - 118 (P x 2) (Pro20) 22:00 - 81 (P x 2) (Pro20)AVG: 121 AVG: 8110:20 - 124 (P x 2) (Pro20) 10:20 - 84 (P x 2) (Pro20) 4 20 mg x 2 15:45 - 121 15:45 - 7621 :14 - 127 (P x 2) (Pro20) 21:14 - 74 (P x 2) (Pro20)AVG: 124 AVG: 789:53 - 127 (P x 2) (Pro20) 9:53 - 86 (P x 2) (Pro20) 4 20 mg x 2 16:00 - 117 16:00 - 7921 :15 - 123 (P x 2) (Pro20) 21 :15 - 80 (P x 2) (Pro20)AVG: 122.3 AVG: 81.79:25 - 122 (P x 2) (Pro20) 9:25 - 71 (P x 2) (Pro20) 4 20 mg x 2 20:56 - 120 20:56 - 7923:18 - 114 (P x 2) (Pro20) 23:18 - 78 (P x 2) (Pro20)AVG: 118.7 AVG: 7610:14 - 114 (P x 2) (Pro10) 10:14 - 77 (P x 2) (Pro10) 4 10 mg x 215:08 - 118 15:08 - 8321 :23 - 124 (P x 2) (Pro10) 21 :23 - 81 (P x 2) (Pro10)AVG: 118.7 AVG: 80.39:25 - 116 (P x 2) (Pro10) 9:25 - 73 (P x 2) (Pro10) 4 10 mg x 2 13:03 - 123 13:03 - 8019:33 - 131 19:33 - 8622:00 - 128 (P x 2) (Pro10) 22:00 - 88 (P x 2) (Pro10)AVG: 124.5 AVG: 81.80:35 - 118 0:35 - 78 4 10 mg x 2 7:26 - 117 7:26 - 738:37 - 128 (P x 2) 8:37 - 83 (P x 2)11 :45 - 130 11 :45 - 8515:15 - 127 15:15 - 7920:50 - 131 (P x 2) (Pro10) 20:50 - 86 (P x 2) (Pro10)22:21 - 121 22:21 - 80AVG: 124.6 AVG: 80.60:43 - 121 0:43 - 76 4 10 mg x 2 9:23 - 123 (P x 2) (Pro10) 9:23 - 79 (Pro x 2)12:30 - 127 (Pro10)21 :15 - 125 (P x 2) (Pro10) 12:30 - 83AVG: 124 21 :15 - 75 (Pro x 2)(Pro10)AVG: 78.39:24 - 122 (P x 2) (Pro10) 9:24 - 73 (P x 2) (Pro10) 4 10 mg x 2 13:18 - 124 13:18 - 7918:09 - 123 18:09 - 7722:25 - 122 (P x 2) (Pro10) 22:25 - 78 (P x 2) (Pro10)AVG: 122.8 AVG: 76.86:24 - 116 6:24 - 76 2 10 mg x 2 10:22 - 125 (P x 2) (Pro10) 10:22 - 75 (P x 2) (Pro10)AVG: 120.5 AVG: 75.55:39 - 123 5:39 - 78 2 10 mg x 2 11:00 - 115 (P x 2) (Pro10) 11 :00 - 76 (P x 2) (Pro10)15:13 - 124 15:13 - 8019:24 - 123 19:24 - 8222:34 - 116 22:34 - 78AVG: 120.2 AVG: 78.89:30 - 119 (P x 2) (Pro10) 9:30 - 80 (P x 2) (Pro10) 4 10 mg x 2 14:56 - 119 14:56 - 8020:30 - 125 (P x 2) 20:30 - 84 (P x 2)22:47 - 116 22:47 - 73AVG: 119.8 AVG: 79.38:29 - 133 (P x 3) (Pro10) 8:29 - 83 (P x 3) (Pro10) 6 10 mg x 2 10:50 - 131 10:50 - 8513:35 - 126 13:35 - 8415:03 - 131 15:03 - 8021 :16 - 134 (P x 3) (Pro10) 21 :16 - 88 (P x 3) (Pro10)AVG: 131 AVG: 847:30 - 126 (P x 2) (Pro20) 7:30 - 82 (P x 2) (Pro20) 4 20 mg, 30 12:00 - 138 12:00 - 91 mg 16:42 - 125 16:42 - 8619:26 - 115 (P x 2) (Pro30) 19:26 - 76 (P x 2) (Pro30)21 :52 - 119 21 :52 - 81AVG: 124.6 AVG: 83.27:30 - 123 (P x 2) (Pro20) 7:30 - 81 (P x 2) (Pro20) 4 20 mg, 30 10:00 - 127 10:00 - 88 mg 14:03 - 124 14:03 - 8320:31 - 131 (P x 2) (Pro30) 20:31 - 83 (P x 2) (Pro30)22:01 - 119 22:01 - 7923:50 - 118 23:50 - 80AVG: 123.7 AVG: 82.39:00 - 123 (P x 2) (Pro20) 9:00 - 86 (P x 2) (Pro20) 4 20 mg, 30 13:35 - 131 13:35 - 83 mg 20:00 - 129 (P x 2) (Pro30) 20:00 - 85 (P x 2) (Pro30)AVG: 127.7 AVG: 84.78:00 - 126 (P x 3) (Pro20) 8:00 - 82 (P x 3) (Pro20) 5 20 mg, 30 20:15 - 119 (P x 2) (Pro30) 20:15 - 76 (P x 2) (Pro30) mg AVG: 122.5 AVG: 7910:10 - 114 (P x 3) (Pro20) 10:10 - 80 (P x 3) (Pro20) 5 20 mg, 30 20:05 - 133 (P x 2) (Pro30) 20:05 - 86 (P x 2) (Pro30) mg AVG: 123.5 AVG: 838:38 - 130 (P x 3) (Pro20) 8:38 - 90 (P x 3) (Pro20) 5 20 mg, 30 12:30 - 133 12:30 - 81 mg 18:30 - 132 18:30 - 8320:30 - 127 (P x 2) (Pro30) 20:30 - 82 (P x 2) (Pro30)AVG: 130.5 AVG: 848:00 - 123 (P x 3) (Pro20) 8:00 - 82 (P x 3) (Pro20) 5 20 mg, 30 13:00 - 123 13:00 - 78 mg18:23 - 126 18:23 - 8422:00 - 123 (P x 2) (Pro30) 22:00 - 83 (P x 2) (Pro30)AVG: 123.8 AVG: 81.857 119 73 3 20 mgAverage % -9.35% +24.7% 2 -6 30 mg x 2 change in BPbetween D1-D36relative to DOAverage % -12.6% +18.2% 4 20 mg x 2 change in BPbetween D37- D40 relative toDOAverage % -11.6% +18.6% 2 -6 10 mg x 2 change in BPbetween D41- D49 relative toDOAverage % -10.5% +21.4% 3 - 5 20 mg, 30 change in BP mg between D50- D57 relative toDOOverall average -10.2% +22.6%% change in BPrelative to DO

[0053] While taking phytase, KS reportedly experienced fewer cravings for food (e.g., red meat), higher quality sleep and energy levels during the day, and an improved overall sense of well-being.

[0054] EXAMPLE 4 - Case Study of Cohort with or without Pre-Hypertension or Potential Risk of High Blood Pressure StateThe present study explored potential effects of phytase on blood pressure. This study was conducted as a short-term, open-label, parallel-group intervention lasting 14 days. A total of 20 adult participants who had been diagnosed with pre-hypertension were allocated into 2intervention groups. A total of 10 participants received Phytase Supplement 1, while the remaining 10 received Phytase Supplement 2.

[0055] Participants were instructed to consume 4 tablets per day for the duration of the study, corresponding to a total expected intake of 56 tablets per participant. Each tablet contained 800 FTU (equivalent to 160 mg) of phytase, resulting in a total daily phytase dose of 3,200 FTU (640 mg). This standardized phytase content was consistent across both supplement formulations. Each participant was instructed to consume each tablet with a meal.

[0056] Each Phytase Supplement 1 capsule or tablet also contained iron (4mg, from ferrous bisglycinate chelate, Ferrochel®), and zinc (2mg). Each Phytase Supplement 2 capsule or tablet also contained a ProbioSEB CSC3™ Proprietary Blend (50mg) of bacillus coagulans, Bacillus subtilis, and Bacillus clausii. Other ingredients in the capsules or tablets included microcrystalline cellulose, hydroxypropyl methylcellulose, maltodextrin, rice bran, MCT oil powder, organic gum arabic, silica, vegetable magnesium stearate, and / or citric acid.

[0057] The outcomes of the study were acceptability and adherence to the supplementation regimen, self-reported tolerability and changes in systolic and diastolic blood pressure. Each participant was instructed to track their diet and measure their blood pressure repeatedly during a one-week pre-supplementation period (i.e., without phytase supplementation), and then to reasonably replicate their diet and continue measuring their blood pressure repeatedly over a two-week supplementation period (i.e., with phytase supplementation), using routine clinical methods. Participants recorded their systolic blood pressure and diastolic blood pressure at one or more timepoints during the 3-week study. Specifically, participants measured their blood pressure at least 1 to 4 times per day, on at least 6 to 7 days per week.

[0058] A total of 20 participants were enrolled in the study, of whom 19 completed the intervention. One participant was lost to follow-up, resulting in a dropout rate of 5%. Among those who completed the study, adherence to the supplementation protocol was remarkably high. Specifically, 17 out of 19 participants reported complete adherence, having consumed all 56 tablets over the 2-week period. The remaining participants also demonstrated nearcomplete adherence, indicating strong overall compliance. For the purposes of the blood pressure analysis below, one participant was omitted as they took an insufficient number of blood pressure measurements per week.

[0059] At baseline, participants had a median age of 57 years, with an interquartile range from 48 to 63 years. The age ranged from 45 to 69 years, indicating that the population consisted primarily of middle-aged and older adults. Among the 19 participants who completed the intervention, 15 were female and 4 were male, indicating that the study population was predominantly female.

[0060] In terms of tolerability, none of the 19 participants who received the supplements reported any adverse events, gastrointestinal complaints, or worsening of existing symptoms during the intervention period. This finding highlights the excellent safety and acceptability profile of both supplement formulations.

[0061] When participants were stratified according to the supplement received (Phytase Supplement 1 vs Phytase Supplement 2), no clear group-level differences or trends were identified, indicating that, at the overall cohort level, supplementation was not associated with measurable changes in blood pressure. Further exploratory analysis revealed a different pattern when participants were stratified based on their individual blood pressure response, as illustrated in Fig. 4A and 4B. Specifically, Group 1 participants (n=8), who had a higher risk of exhibiting a high blood pressure state or pre-hypertension, reported and demonstrated a consistent trend toward reduced systolic and diastolic blood pressure across timepoints. In contrast, the other subgroup of participants, Group 2, (n=10), who had little to no risk of developing high blood pressure or were not considered pre-hypertensive, showed relatively stable blood pressure values over time, with no evident improvement.

[0062] As illustrated in Fig. 4A and 4B, participants exhibiting a blood pressure response (i.e., Group 1, in black) demonstrated a consistent downward trend in their average systolic and diastolic blood pressures across successive timepoints during the supplementation period (T1 and T2) relative to the pre-supplementation period (TO), whereas Group 2 (in grey) showed no such trend. Identification of participants exhibiting a blood pressure response did not require specialized diagnostic testing or advance stratification. Rather, Group 1 participants were identified based on observed changes in blood pressure before and during ongoing phytase supplementation, consistent with a before-after monitoring approach commonly employed in nutritional and metabolic interventions. This allows practical use of the supplementation regimen in a general adult population, with continued administration being guided by observed physiological response.

[0063] Liver function parameters were within the normal reference range at baseline for all participants (see Table 4). No clinically relevant abnormalities were observed prior tothe initiation of the intervention. At study completion, liver function tests remained within normal limits and showed no meaningful changes compared to baseline values, indicating that supplementation was not associated with any adverse effects on hepatic function over the duration of the study.

[0064] Table 4. Liver function parameters were within the normal reference range at baseline for all participants.Statistics (N = 19)Variable Timepoint Minimum Q1 Median Q3 Maximum AST (SGOT) tl 12.000 17.000 20.000 23.000 24.000 t3 11.000 18.000 20.000 23.000 29.000 ALT (SGPT) tl 8.00 12.00 16.00 19.00 45.00 t3 9.00 12.00 16.00 22.00 29.00 Gamma- GT tl 9.00 12.00 15.00 19.00 28.00t3 9.00 13.00 15.00 18.00 32.00

[0065] With respect to exploratory clinical outcomes, 8 out of 19 participants experienced a noticeable reduction in either systolic and / or diastolic blood pressure. These participants were evenly distributed between the 2 intervention groups, with 4 individuals in the Phytase Supplement 1 group and 4 in the Phytase Supplement 2 group demonstrating improvements. This balanced distribution suggests that the observed effect is unlikely to be attributable to formulation-specific components such as probiotics, iron, or zinc, and may instead be associated with the shared phytase component of the supplements. No significant changes were observed in markers of iron or zinc status over the course of the intervention (see Table 5). Biomarker levels remained stable from baseline to study completion, indicating that the 14-day supplementation period did not result in measurable alterations in iron or zinc status within this cohort.

[0066] Table 5. Markers of iron or zinc status over the course of the intervention.Statistics (N = 19)Variable Timepoint Minimum Q1 Median Q3 Maximum Serum tl 41.00 79.00 105.00 114.00 169.00 Iron (Fe,ug / dLjt3 62.00 83.00 93.00 120.00 133.00 Serum tl 88.10 92.00 94.00 102.00 117.00 Zinc (Zn,ug / rll / it3 89.20 90.50 96.20 103.30 115.80

[0067] Quality of life was assessed using the WHOQOL-BREF, a 26-item, selfadministered questionnaire developed by the World Health Organization to evaluate an individual’s perception of quality of life across 4 domains, including physical health, psychological health, social relationships, and environment. Overall, no statistically significant changes were observed across timepoints in the total or domain-specific scores (see Table 6).

[0068] Table 6. Quality of life was assessed using the WHOQOL-BREF Statistics (N = 19)Variable Timepoint Minimum Q1 Median Q3 Maximum WHOQOL-BREF Total Score tl 69.00 88.00 96.00 101.00 109.00t2 63.00 93.00 96.00 105.00 112.00t3 79.00 92.00 98.00 103.00 113.00

[0069] However, in a subgroup analysis of participants who exhibited improvements in blood pressure, a trend toward enhanced self-perceived quality of life was observed, suggesting a potential association between physiological improvements and subjective wellbeing (see Tables 7 and 8).

[0070] Table 7. Quality of life was assessed using the WHOQOL-BREF for NonResponder.Results for BP Average Response = Non-Responder (N = 11)StatisticsVariable Timepoint Minimum Q1 Median Q3 Maximum WHOQOL-BREF Total Score tl 69.00 83.00 96.00 101.00 109.00 t2 63.00 75.00 94.00 96.00 112.00t3 30.00 87.00 97.00 103.00 113.00

[0071] Table 8. Quality of life was assessed using the WHOQOL-BREF for Responders.Results for BP Average Response = Responder (N=8)StatisticsVariable Timepoint Minimum QI Median Q3 Maximum WHOQOL-BREF Total Score tl 86.00 93.50 95.50 101.75 107.00t2 82.00 94.50 100.00 105.75 107.00t3 79.00 94.50 101.00 105.75 107.00

[0072] This study provides important evidence on the acceptability, adherence, safety, and potential physiological effects of phytase-containing dietary supplements in adults with treatment naive prehypertension or hypertension. The intervention was associated with exceptionally high adherence, with 17 out of 19 participants reporting full compliance, and no reported adverse events or worsening of symptoms. These findings indicate that both Phytase Supplement 1 and Phytase Supplement 2 are well tolerated and feasible for use in this population.

[0073] No measurable changes were observed in markers of iron or zinc status over the 14-day intervention period.

[0074] Subgroup analyses revealed that 8 out of 18 participants exhibited a consistent reduction in blood pressure over time. Importantly, this effect was not confined to a specific supplement group, suggesting that the shared phytase component, administered at a dose of 3,200 FTU (640 mg) per day, may underlie this observation. In line with these findings, quality of life, as assessed by the WHOQOL-BREF, did not change significantly at the group level. However, participants who experienced improvements in blood pressure also demonstrated a trend toward enhanced self-perceived quality of life. This suggests a possible link between physiological improvements and subjective well-being, although causality cannot be established within the current study design.

[0075] Liver function tests remained within normal ranges throughout the study, providing further evidence of the safety profile of the intervention. Overall, the results support the hypothesis that phytase supplementation is safe and acceptable.

Claims

WHAT IS CLAIMED IS:

1. A method for preventing or treating hypertension in a subject in need thereof, comprising administering phytase to the subject.

2. The method of claim 1, wherein the subject exhibits a reduction in systolic and / or diastolic blood pressure following administration of the phytase.

3. The method of claim 2, wherein the reduction in systolic and / or diastolic blood pressure is observable from about 7 days to about 14 days following initiation of administration of the phytase.

4. The method of any one of claims 1-3, wherein the subject is administered from about 400 FTU to about 1,000,000 FTU of phytase per day.

5. The method of any one of claims 1-4, wherein the subject is administered from about 400 FTU to about 5000 FTU of phytase per day.

6. The method of any one of claims 1-5, wherein the subject is measured at least once as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, at least once prior to being administered an initial dose of the phytase.

7. The method of any one of claims 1-6, wherein the subject is measured as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

8. A method for preventing or treating elevated blood pressure in a subject in need thereof, comprising administering phytase to the subject.

9. The method of claim 8, wherein the subject exhibits a reduction in systolic and / or diastolic blood pressure following administration of the phytase.

10. The method of claim 9, wherein the reduction in systolic and / or diastolic blood pressure is observable from about 7 days to about 14 days following initiation of administration of the phytase.

11. The method of any one of claims 8-10, wherein the subject is administered from about 400 FTU to about 1,000,000 FTU of phytase per day.

12. The method of any one of claims 8-11, wherein the subject is administered from about 400 FTU to about 5000 FTU of phytase per day.

13. The method of any one of claims 8-12, wherein the subject is measured at least once as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, at least once prior to being administered an initial dose of the phytase.

14. The method according to any one of claims 8-13, wherein the subject is measured as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

15. The method of any one of claims 1-14, wherein the phytase is administered in a dose of from about 190 FTU to about 2000 FTU, for example, about 800 FTU.

16. The method of any one of claims 1-15, wherein the phytase is administered once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day, 10 times per day, 11 times per day, 12 times per day, 13 times per day, 14 times per day, 15 times per day, 16 times per day, 17 times per day, 18 times per day, 19 times per day, 20 times per day, 21 times per day, 22 times per day, 23 times per day, 24 times per day, 25 times per day, 26 times per day, or more.

17. The method of any one of claims 1-16, wherein the phytase is administered to the subject for a duration of from about 1 day to about 360 days, for example, about 28 days, or for the lifetime of the subject.

18. The method of any one of claims 1-17, wherein the subject is suffering from one or more of the following symptoms: severe headache, chest pain, dizziness, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack, or heart failure.

19. The method of any one of claims 1-18, wherein the phytase is co-administered with one or more of the following anti-hypertensive medication(s): an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a calcium channel blocker, a diuretic, Sandoz Valsartan HCT, a statin, an anti-platelet medication, an anti-coagulant, a nitrate, an aldosterone antagonist, Digoxin, an anti-arrhythmic medication, a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor, or an angiotensin receptor-neprilysin inhibitor (ARNI).

20. The method of claim 19, wherein the phytase is co-administered concurrently with the one or more anti-hypertensive medication(s).

21. The method of claim 19, wherein the phytase is co-administered non-concurrently with the one or more anti-hypertensive medication(s).

22. The method of any one of claims 1-21, wherein the phytase is a wild-type phytase sourced from Aspergillus ficuum or Aspergillus niger.

23. The method of any one of claims 1-21, wherein the phytase is a wild-type phytase sourced from a species of fungi of the genera Myceliophthora, Mucor, Penicillium, Rhizopus, or Trichoderma.

24. The method of any one of claims 1-23, wherein the phytase is administered orally.

25. The method of any one of claims 1-24, wherein the phytase is administered at a total daily dose of about 3200 FTU.

26. The method of any one of claims 1-25, further comprising monitoring systolic and / or diastolic blood pressure during a trial period following initiating administration of the phytase, and continuing administration when a reduction in systolic and / or diastolic blood pressure is observed.

27. The method of claim 26, wherein monitoring comprises obtaining at least two blood pressure measurements on at least two occasions during the trial period and comparing to a baseline blood pressure.

28. The method of any one of claims 1-27, wherein the subject has prehypertension or stage 1 hypertension prior to administration.

29. The method of any one of claims 1-28, wherein the phytase is co-administered with propranolol.

30. Use of phytase for preventing or treating hypertension in a subject.

31. The use of claim 30, wherein about 400 FTU to about 1,000,000 FTU of phytase is for administration to the subject per day.

32. The use of claim 30 or 31 , wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

33. Use of phytase for preparation of a medicament for preventing or treating hypertension in a subject.

34. The use of claim 33, wherein about 400 FTU to about 1,000,000 FTU of phytase is for administration to the subject per day.

35. The use of claim 33 or 34, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

36. Use of a composition comprising phytase for preventing or treating hypertension in a subject, wherein the composition is for administration to the subject.

37. The use of claim 36, wherein about 400 FTU to about 1,000,000 FTU of phytase is for administration to the subject per day.

38. The use according to claim 36 or 37, wherein the composition comprises from about 190 FTU to about 2000 FTU of phytase.

39. The use according to any one of claims 36-38, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient, zinc, micronutrient, vitamin, and / or mineral.

40. Phytase for use in preventing or treating hypertension in a subject.

41. The phytase for use according to claim 40, wherein about 400 FTU to about 1 ,000,000 FTU of phytase is for administration to the subject per day.

42. The phytase for use according to claim 40 or 41, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

43. A composition comprising phytase for use in preventing or treating hypertension in a subject, wherein the composition is for administration to the subject.

44. The composition for use according to claim 43, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

45. The composition for use according to claim 43 or 44, wherein the composition comprises from about 190 FTU to about 2000 FTU of phytase.

46. The composition for use according to any one of claims 43-45, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient, zinc, micronutrient(s), vitamin(s), and / or mineral(s).

47. The use of any one of claims 30-39, the phytase for use of any one of claims 40-42, or the composition for use of any one of claims 43-46, wherein the subject exhibits a reduction in systolic and / or diastolic blood pressure following administration.

48. The use, phytase for use, or composition for use of claim 47, wherein the reduction in systolic and / or diastolic blood pressure is observable from about 7 days to about 14 days following initiation of administration.

49. The use of any one of claims 30-39, the phytase for use of any one of claims 40-42, the composition for use of any one of claims 43-46, or the use, phytase for use, or composition for use of any one of claims 47-48, wherein the subject is measured at least once as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, at least once prior to the administration of an initial dose of the phytase.

50. The use of any one of claims 30-39, the phytase for use of any one of claims 40-42, the composition for use of any one of claims 43-46, or the use, phytase for use, or composition for use of any one of claims 47-49, wherein the subject is measured as having a systolic blood pressure at or above 130 mmHg, and / or a diastolic blood pressure at or above 80 mmHg, on at least three or more days during a three-month period preceding the administration of an initial dose of the phytase.

51. Use of phytase for preventing or treating elevated blood pressure in a subject.

52. The use of claim 51 , wherein about 400 FTU to about 1 ,000,000 FTU of phytase is for administration to the subject per day.

53. The use of claim 51 or 52, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

54. Use of phytase for preparation of a medicament for preventing or treating elevated blood pressure in a subject.

55. The use of claim 54, wherein about 400 FTU to about 1,000,000 FTU of phytase is for administration to the subject per day.

56. The use of claim 54 or 55, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

57. Use of a composition comprising phytase for preventing or treating elevated blood pressure in a subject, wherein the composition is for administration to the subject.

58. The use of claim 57, wherein about 400 FTU to about 1,000,000 FTU of phytase is for administration to the subject per day.

59. The use according to claim 57 or 58, wherein the composition comprises from about 190 FTU to about 2000 FTU of phytase.

60. The use according to any one of claims 57-59, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient, zinc, micronutrient, vitamin, and / or mineral.

61. Phytase for use in preventing or treating elevated blood pressure in a subject.

62. The phytase for use according to claim 61, wherein about 400 FTU to about 1 ,000,000 FTU of phytase is for administration to the subject per day.

63. The phytase for use according to claim 61 or 62, wherein about 400 FTU to about 5000 FTU of phytase is for administration to the subject per day.

64. A composition comprising phytase for use in preventing or treating elevated blood pressure in a subject, wherein the composition is for administration to the subject.

65. The composition for use according to claim 64, wherein the composition comprises from about 190 FTU to about 1,000,000 FTU of phytase.

66. The composition for use according to claim 64 or 65, wherein the composition comprises from about 190 FTU to about 2000 FTU of phytase.

67. The composition for use according to any one of claims 64-66, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient, zinc, micronutrient, vitamin, and / or mineral.

68. The use of any one of claims 51-60, the phytase for use of any one of claims 61-63, or the composition for use of any one of claims 64-67, wherein the subject exhibits a reduction in systolic and / or diastolic blood pressure following administration.

69. The use, phytase for use, or composition for use of claim 68, wherein the reduction in systolic and / or diastolic blood pressure is observable from about 7 days to about 14 days following initiation of administration.

70. The use of any one of claims 51-60, the phytase for use of any one of claims 61-63, the composition for use of any one of claims 64-67, or the use, phytase for use, or composition for use of any one of claims 68-69, wherein the subject is measured at least once as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, at least once prior to being administered an initial dose of the phytase.

71. The use of any one of claims 51-60, the phytase for use of any one of claims 61-63, the composition for use of any one of claims 64-67, or the use, phytase for use, or composition for use of any one of claims 68-70, wherein the subject is measured as having a systolic blood pressure from about 121 mmHg to about 129 mmHg and a diastolic blood pressure less than 80 mmHg, on at least three or more days during a three-month period preceding the subject being administered an initial dose of the phytase.

72. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-71, wherein the phytase or the composition is for administration at a dose of from about 190 FTU to about 2000 FTU, for example, about 800 FTU.

73. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-72, wherein the phytase or the composition is for administration once per day, twice per day, three times per day, four times per day, five times per day, six times per day, seven times per day, eight times per day, nine times per day, 10 times per day, 11 times per day, 12 times per day, 13 times per day, 14 times per day, 15 times per day, 16 times per day, 17 times per day, 18 times per day, 19 times per day, 20 times per day, 21 times per day, 22 times per day, 23 times per day, 24 times per day, 25 times per day, 26 times per day, or more.

74. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-73, wherein the phytase or the composition is for administration to the subject for a duration of from about 1 day to about 360 days, for example, about 28 days, or for the lifetime of the subject.

75. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-74, wherein the subject is suffering from one or more of the following symptoms: severe headache, chest pain, dizziness, difficulty breathing, nausea, vomiting, blurred vision or other vision changes, anxiety, confusion, memory loss, buzzing in the ears, nosebleeds, arrhythmia, heart attack, or heart failure.

76. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, orthe use, phytase for use, or composition for use of any one of claims 47-50 and 68-75, wherein the phytase or the composition is for co-administration with one or more of the following anti-hypertensive medication(s): an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a calcium channel blocker, a diuretic, Sandoz Valsartan HCT, a statin, an anti-platelet medication, an anti-coagulant, a nitrate, an aldosterone antagonist, Digoxin, an anti-arrhythmic medication, a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor, or an angiotensin receptor-neprilysin inhibitor (ARNI).

77. The use, phytase for use, or composition for use of claim 76, wherein the phytase or the composition is for co-administration concurrently with the one or more anti-hypertensive medication(s).

78. The use, phytase for use, or composition for use of any one of claim 76, wherein the phytase is for co-administration non-concurrently with the one or more anti-hypertensive medication(s).

79. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-78, wherein the phytase is a wild-type phytase sourced from Aspergillus ficuum or Aspergillus niger.

80. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-79, wherein the phytase is sourced from a species of fungi of the genera Myceliophthora, Mucor, Penicillium, Rhizopus, or Trichoderma.

81. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-80, wherein the administration is oral administration.

82. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-81, wherein the phytase is for administration at a total daily dose of about 3200 FTU.

83. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-82, further comprising monitoring systolic and / or diastolic blood pressure during a trial period following initiating administration of the phytase, and wherein the phytase is for continued administration when a reduction in systolic and / or diastolic blood pressure is observed.

84. The use, phytase for use, or composition for use of claim 83, wherein monitoring comprises obtaining at least two blood pressure measurements on at least two occasions during the trial period and comparing to a baseline blood pressure.

85. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-84, wherein the subject has prehypertension or stage 1 hypertension prior to administration.

86. The use of any one of claims 30-39 and 51-60, the phytase for use of any one of claims 40-42 and 61-63, the composition for use of any one of claims 43-46 and 64-67, or the use, phytase for use, or composition for use of any one of claims 47-50 and 68-85, wherein the phytase is for co-ad ministration with propranolol.